Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 mg Psilocybin Clear all

Conditions: PTSD
Interventions: psilocybin, Supportive Therapy, Prolonged Exposure Therapy; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Anna Rose Childress, Ph.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Binge Eating Disorder
Interventions: TRYP-0082, Psychotherapy; Drug · Behavioral
Lead sponsor: TRYP Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Major Depression
Interventions: Psilocybin (Usona Institute), Propofol, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
Interventions: Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone, Sham taVNS; Drug · Device · Behavioral + 1 more
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
Interventions: Psilocybin, Niacin; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 25 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Perception Disturbance, Visual Suppression, Psychedelic Experiences
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 25 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Participants With Lower-than-average Mental Well-being
Interventions: Psilocybin, Context 1, Context 2, Placebo; Drug · Behavioral
Lead sponsor: Robin Carhart-Harris, PhD, MA; Other
Eligibility: 21 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Tobacco Use Disorder
Interventions: Psilocybin, Niacin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Baltimore, Maryland • New York, New York

Conditions: Chronic Low-back Pain, Depression
Interventions: Psilocybin, Methylphenidate; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low-back Pain
Interventions: Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo; Drug
Lead sponsor: Joshua Woolley, MD, PhD; Other
Eligibility: 25 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more

Conditions: Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions: Psilocybin; Drug
Lead sponsor: Robin Carhart-Harris, PhD, MA; Other
Eligibility: 21 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anorexia Nervosa
Interventions: Psilocybin; Drug
Lead sponsor: COMPASS Pathways; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Austin, Texas

Conditions: Alcohol Use Disorder
Interventions: Psilocybin, Inactive Placebo, Supportive therapy sessions; Drug · Other · Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Demoralization
Interventions: Psilocybin, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cocaine-Related Disorders
Interventions: Psilocybin, Diphenhydramine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Prolonged Grief Disorder
Interventions: Psilocybin 25 mg, Functional Magnetic Resonance Imaging (fMRI); Drug · Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Opioid Use Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Low Back Pain (CLBP), Physical Therapy, Psilocybin
Interventions: Psilocybin 10 mg, Psilocybin 25 mg, Niacin 100 mg; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psilocybin, Music Intervention
Interventions: Psilocybin (high dose), Playlist 1, Playlist 2, Playlist 3, Playlist 4, Playlist 5; Drug · Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cluster Headache
Interventions: 0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Psilocybin, Neuropathy
Interventions: Psilocybin (drug), Standard of Care (SOC); Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcohol Use Disorder (AUD), PTSD
Interventions: Psilocybin 25 mg, Maltodextrin (Placebo); Drug
Lead sponsor: Nathan Brashares Sackett; Other
Eligibility: 21 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Psilocybin-Assisted Therapy

Wellcome Leap Psilocybin for OUD

Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Study of Psilocybin Under Anesthesia Controlled by EEG

The ENHANCE Study: taVNS and Psilocybin

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Psilocybin in Chronic Low Back Pain and Depression

Psilocybin Therapy for Chronic Low Back Pain

Psilocybin for Opioid Use Disorder (OUD)

Neural and Physiological Correlates of Psychedelic Sub-states

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD

Exploratory Study of Low Dose Psilocybin

Psilocybin-facilitated Treatment for Cocaine Use

Psilocybin for Prolonged Grief Disorder

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

Psilocybin for the Treatment of Cluster Headache

NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)